Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...
Dalam sidang ke-21 Dewan Pers di Bandung, Jawa Barat pada 19 Februari 1981, gagasan tersebut akhirnya disetujui dan diajukan kepada pemerintah. Setelah melalui berbagai pertimbangan, pemerintah ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback